Merz Pharma

Merz Pharma GmbH & Co. KGaA is a privately-held pharmaceutical company based in Frankfurt, Germany with affiliates across Europe, as well as the US, Canada, Mexico, Brazil and Asia Pacific and regional headquarters in Singapore and North Carolina, USA.

Merz Pharma GmbH & Co. KGaA.
Private
IndustryPharmaceuticals
Founded09 March 1908
HeadquartersFrankfurt am Main
Key people
  • Andreas Krebs, Chairman, Philip Burchard, Chief Executive Officer
Revenue€1.024,4 million (2017/2018)
Number of employees
3,151
Websitewww.merz.com

The company is active in research, development and distribution of innovative products in the areas of aesthetic medicine and neurologically induced movement disorders. In German-speaking countries, our consumer products segment, Merz Consumer Care, is a leading provider of innovative health, wellness and beauty products with its well-known tetesept® [1] and Merz Spezial®[2] brands.

Today, Merz’s global business is focused on the areas of medical aesthetics and neurotoxin therapy, supported by a number of successful regional brands in both the prescription medicine and consumer health and beauty sectors. Key brands in the portfolio include Belotero®, Radiesse, Cellfina, Ultherapy, Botulinum Toxin and Neocutis (US only).[3]

History

Merz has been a successful specialty healthcare company for more than 110 years. The company was founded in 1908 in Frankfurt, Germany by a 24-year old chemist named Friedrich Merz, and is still owned by the fourth-generation of the Merz family.[4]

1908 – Company founded

1911 – Introduction of first topical contraceptive Patentex

1953 – Launch of anti-wrinkle moisturizing cream Placentubex®

1964 – Development of Merz Spezial Dragees from 18 different active ingredients

1965 – Introduction of tetesept bath medicine[5]

1968 – Launch of Placentubex® Foaming Mask

2002 – Introduction of Memantine for the treatment of Alzheimer’s disease

2005 – Merz launches a next generation of Botulinum Toxin

2010 – Acquisition of Bioform and its flagship product RADIESSE®

2013 – Acquisition of Anteis and its range of dermal fillers, Belotero®

2013 – Acquisition of Swiss skincare company Neocutis[6]

2014 – Acquisition of the Ulthera® System, the first ultrasound platform device with FDA clearance

2015 – Launch of Radiesse® (+) Lidocaine in the US market

2015 – Establishment of Asia Pacific regional Headquarters in Singapore

2016 – Acquisition of ON Light Sciences with its flagship product DeScribe®

2016 – Launch of the Cellfina® System in the US, minimally-invasive cellulite treatment

2018 – Launch of Belotero® Lips[7]

2019 - Launch of Belotero® Revive[8]

gollark: For what purpose?
gollark: These have been certified non-ominous by the GTech™ certification pentachoron.
gollark: We theorize that this is due to bee field effects on the geometry of local space-time.
gollark: ↓ all HTech™ sites
gollark: You should advertise better things, like potatOS™.

References
  1. "tetesept.de". tetesept.de (in German). Retrieved 2019-08-06.
  2. "Merz Spezial" (in German). Retrieved 2019-08-06.
  3. "Products". Merz Pharma. Retrieved 2019-08-06.
  4. "History". Merz Pharma. Retrieved 2019-08-06.
  5. "tetesept.de". tetesept.de (in German). Retrieved 2019-08-06.
  6. "Merz Pharma Group Acquires Swiss Dermatology Company Neocutis S.A." www.businesswire.com. 2013-07-31. Retrieved 2019-08-06.
  7. "Merz Aesthetics Launches New Belotero® Lips Dermal Filler Products". www.businesswire.com. 2018-04-09. Retrieved 2019-08-06.
  8. "Merz Launches New Belotero® Revive Dermal Filler". www.businesswire.com. 2019-04-05. Retrieved 2019-08-06.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.